The first FDA-approved prescription medication for the treatment of primary hyperoxaluria type 1 (PH1).

OXLUMO® (lumasiran) is a prescription medicine for the treatment of PH1 to lower oxalate in urine and blood in children and adults.

Tell Me About OXLUMO® Learn More About PH1

Natalie
Person with PH1*

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

OXLUMO works by reducing oxalate production in infants, children, and adults

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.

Show Me the Results

What to expect from treatment with OXLUMO

Learn about how OXLUMO is given.

Take Me There

Get Started With OXLUMO

CONNECT WITH AN ALNYLAM EDUCATOR

Learn about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO® from one of our trained Alnylam Patient Education Liaisons (PELs).

PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.

Let’s Connect

We’re here to help you access therapy

Find support services that can help you and your family during treatment with OXLUMO.

Let’s Go

Sign up for updates

Learn more by signing up to receive important content.

Sign Me Up

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.

For additional information about OXLUMO, please see full Prescribing Information.